StocksMedium•10 November 2026•
1 min read
Braveheart Bio Reports $503.5 Million Cash Position and Sets LIONHEART-HCM Trial Timeline
Key Facts
1Braveheart Bio reported cash, cash equivalents, and investments of $503.5 million, with a runway expected into 2029.
2An interim analysis for the Phase 3 LIONHEART-HCM study is expected in the second half of 2027.
Braveheart Bio reported cash, cash equivalents, and investments totaling $503.5 million for the third quarter of 2026. The company stated in a GlobeNewswire release that its current liquidity is expected to provide a financial runway into 2029. Additionally, an interim analysis for the Phase 3 LIONHEART-HCM study is scheduled to take place in the second half of 2027.
The stock of BRVE closed at $19.46 on November 9, 2026, after trading between a session low of $18.61 and a high of $19.87. These financial results highlight the company's focus on maintaining a stable cash position to support its clinical pipeline development, including the BHB-1893 program, according to the quarterly update.